Finerenone was found to reduce heart failure events and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). The FINEARTS-HF trial showed significant positive outcomes with finerenone compared to a placebo, with a reduction in total worsening HF events and cardiovascular death. The trial included over 6,000 patients across 37 countries and the results were consistent across different subgroups. While there was no difference in all-cause mortality or kidney outcomes between the groups, finerenone did increase the risk of hyperkalemia but lowered the risk of hypokalemia. The findings suggest finerenone could be a new treatment option for HFmrEF/HFpEF patients in addition to SGLT2 inhibitors.
Source link
FINEARTS-HF trial shows finerenone benefits for heart failure with preserved ejection fraction
